Skip to main content

TGA grants provisional determination for the Moderna bivalent COVID-19 vaccine "SPIKEVAX Bivalent Zero/Omicron"

On 27 April 2022 the TGA granted a provisional determination to Moderna Australia Pty Ltd in relation to its bivalent COVID-19 vaccine, elasomeran/elasomeran 0-omicron (SPIKEVAX Bivalent Zero/Omicron).

Related content

Help us improve the Therapeutic Goods Administration site